10月29日,上海医药(601607)公布2026年三季报,公司营业收入为2229.64亿元,同比上升3.7%;归母净利润为45.86亿元,同比下降10.9%;扣非归母净利润为33.74亿元,同比上升25.02%;经营现金流净额为53.47亿元,同比增长127.5%;EPS(全面摊薄)为1.24元。 其中第三季度,公司营业收入为754.94亿元,同比上升2.7%;归母净利润为10.82亿元,同比...
Source Link10月29日,上海医药(601607)公布2026年三季报,公司营业收入为2229.64亿元,同比上升3.7%;归母净利润为45.86亿元,同比下降10.9%;扣非归母净利润为33.74亿元,同比上升25.02%;经营现金流净额为53.47亿元,同比增长127.5%;EPS(全面摊薄)为1.24元。 其中第三季度,公司营业收入为754.94亿元,同比上升2.7%;归母净利润为10.82亿元,同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.